Friday, April 18, 2014 9:49:07 AM
Medical Greens (SKTO) Announces Licensing of Proprietary Cryo-Extraction Technique for Extracting Non-Psychoactive Cannabinoids
LOS ANGELES, CA--(Marketwired - Jan 10, 2014) - SK3 Group, Inc (OTC Pink: SKTO) is pleased to announce that it has completed the licensing agreements between Berkeley Bio-Organic Research Laboratories, LLC and its managed wholesale collectives to produce non-psychoactive mixed cannabinoid carboxylates (Dharmanol™). The licensing agreement covers the proprietary methods developed by Berkeley Bio -- known as cryo-extraction -- used to extract the cannabinoids and preserve them in their non-psychoactive state.
"We are happy to have put together more of the elements necessary to fill the large demand anticipated for our Dharmanol™ product line," said Artemus Mayor, President of SK3 Group. "Dr. Charles Apel and David Hoye have developed a unique technique for extracting the non-psychoactive but effective components of cannabis that we believe will prove to be the key to bringing an entirely new dimension to the field of nutritional supplements in the United States and greater access to the beneficial effects of medical marijuana."
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM